We have previously described the engineering and preclinical characterization of TVTfR, an Fc-based human TfR-targeted drug delivery platform that has enabled antibody-, enzyme- and protein-based programs to advance towards clinical evaluation in Alzheimer’s disease, neuronopathic lysosomal storage disease, and frontotemporal degeneration36,37. The gene discussed is TFRC; the disease is early-onset autosomal dominant Alzheimer disease.